Service Description Rate Unit Service Limits Combination of Service Rules

Similar documents
COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2018) Provider Type 32: Opioid Treatment Program

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Jan 1, 2018)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff Aug 1, 2017)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2017)

COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff May 15, 2017)

Medicaid Treatment and Service Fees for Substance Use Disorder (SUD): CY

2017 Drug Screen Tests

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

MEDICAL POLICY Drug Testing

MEDICAL POLICY Drug Testing

Drug Testing Policy. Approved By 05/10/2017. Application This reimbursement policy applies to UnitedHealthcare Community Plan Medicaid products.

MEDICAL POLICY No R2 DRUG TESTING

Medical Policy Outpatient Drug Screening and Testing. No Prior Authorization X X

Opioid Treatment Program Reimbursement Re-bundling Proposal

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: October 1, Related Policies None

Payment Policy Drug Testing EFFECTIVE DATE: POLICY LAST UPDATED:

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: January 1, Related Policies None

DRUG TESTING POLICY. Policy Number: ADMINISTRATIVE T0 Effective Date: March 1, Related Policies None

Drug Testing Policy. Approved By 06/14/2017

2017 Drug Screening Code Updates for WV Medicaid. Prior Authorization for Drug Screening Codes Beyond Service Limits

2018 Drug Screening Code Updates for WV Medicaid

Payment Policy: Urine Specimen Validity Testing Reference Number: CC.PP.056 Product Types: ALL Effective Date: 11/01/2017 Last Review Date:

Drug Testing Policy. Reimbursement Policy CMS Approved By. Policy Number. Annual Approval Date. Reimbursement Policy Oversight Committee

B. To assess an individual when clinical evaluation suggests use of non-prescribed medications or illegal substances; or

Prevention of Fetal Alcohol Spectrum Disorder Coding Basics

Addiction and Recovery Treatment Services (ARTS) Reimbursement Structure

Clinical Drug Screening and/or Drug Testing

Clinical Drug Screening and/or Drug Testing

MAGELLAN VA MEDICAID/DMAS RATES

MAGELLAN VA MEDICAID/DMAS RATES

DMHAS ASAM SERVICE DESCRIPTIONS

distinguish between structural isomers (but not necessarily stereoisomers), including, but not

Controlled Substance Monitoring and Drugs of Abuse Testing Determination

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Calendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations

Cigna Medical Coverage Policy

PROCEDURE CODES & UNIT

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Clinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder

BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES

Based on our criteria and assessment of the peer-reviewed literature, presumptive (immunoassay) in office or pointof-care

In-OfficeLabTesting. Effective date: August 1, 2017

In Office Lab Testing

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Policy: Outpatient Testing for Drugs of Abuse Reference Number: CP.MP.HN 542

Claims Edit Guideline: Drug Testing

Clinical UM Guideline

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

Clinical Policy: Buprenorphine-Naloxone (Suboxone, Bunavail, Zubsolv) Reference Number: CP.PMN.XX. Line of Business: Medicaid

Medicaid and the Opioid Crisis

See Important Reminder at the end of this policy for important regulatory and legal information.

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

VIRGINIA MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) OFFICE BASED OPIOID PROVIDER (OBOT) PAYMENT MODEL 3 rd Annual Mental Health Summit

Behavioral Health Authorization Requirements*

Policy Evaluation: Substance Use Disorders

VIRGINIA MEDICAID PERSPECTIVE ON BEST PRACTICES IN THE TREATMENT OF OPIOID USE DISORDER

URINE DRUG TESTING FOR SUBSTANCE ABUSE TREATMENT AND CHRONIC PAIN MANAGEMENT

State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment

Urine Drug Testing for Substance Use and Pain Management

Frequently Asked Questions about Florida s Opioid STR Grant

Closing the Loop in Treating Opioid Addiction:

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS

Contractor Information. LCD Information

Medical Necessity Criteria 2017

Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents

PERSPECTIVE FROM VIRGINIA: SUCCESS ADDRESSING THE OPIOID CRISIS THROUGH MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS)

Addiction Recovery Treatment Services (ARTS): Billing Best Practices. December 2017

PROCEDURE CODES & UNIT

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Community Behavioral Health Services. Fee Schedule

Corporate Medical Policy

Virginia Medicaid Peer Support Services UM Guideline

Management Options for Opioid Dependence:

The CARA & Buprenorphine Prescribing for APNs & PAs

Comment Number. Date Comment Received

Prepublication Requirements

Medication-Assisted Treatment. What Is It and Why Do We Use It?

RI Centers of Excellence for the

State Opioid Response (SOR) Grant

Page 1 of 11. Effective 9/15/2018 AUTHORIZATION REQUIREMENT LEVEL OF CARE. Notes (0 = No Additional Comments)

Vermont Hub and Spoke Model Treatment Need Questionnaire

32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)

Clinical Policy: Outpatient Testing for Drugs of Abuse

COURT OF COMMON PLEAS DRUG DIVERSION PROGRAM

AUTHORIZATION RQUIREMENTS Notes (0= No Additional Comments) 101 All inclusive room and board On 0

Opioid State Targeted Response (STR) Project

Coding for Preventive Services A Guide for HIV Providers

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

ADDICTION AND RECOVERY OPIOID CRISIS

Medication-Assisted Treatment (MAT) Overview

Massachusetts Medicaid pediatric high-risk asthma bundled payment pilot

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines

Vivitrol Drug Court and Medication Assisted Treatment

Transcription:

Provider Type 32: Opioid Treatment Program COMMUNITY-BASED SUBSTANCE USE DISORDER FEE SCHEDULE (eff July 1, 2018) Updates for IMD Residential Services, J s Eff 1-1-19 and Drug Screening s Eff 2-1-19 H0001 Alcohol and/or Drug Assessment $152.91 Per assessment H0004 Individual Outpatient Therapy $21.54 H0005 Group Outpatient Therapy $42.00 MAT Initial induction: Alcohol/Drug H0016 Services; Medical/Somatic (Medical Intervention in Ambulatory Setting) Methadone Services $215.36 Per 15 minute increment Per 60-90 minute session Initial Induction period Can only be billed once per 12-months per participant per provider unless there is more than a 30 day break in treatment. Providers may not bill for more than six units per day per participant. Cannot bill with H0015 or H2036 (billed by PT 50) Provider may not bill for more than one Level I Group counseling session per day per participant. Provider may bill once per seven days only in the first week of treatment or after a break in treatment of 6 months. Provider may bill once per seven days when the patient has been seen at least H0020: Methadone Maintenance $66.51 Per Week once during the month; Providers may bill with Induction during the first week only. W9520 Methadone guest dosing $9.50 Buprenorphine Services Ongoing services (Buprenorphine/Naloxone): H0047 Alcohol/Other Drug Abuse Services, Not Otherwise Specified Per day receiving medication at guest program Guest dosing may be billed once per day that the patient is receiving their medication at the guest dosing program. One patient is eligible for up to 30 days of guest dosing per year. Additional days may be used with clinical reasoning. N/A Cannot bill with H0015 or H2036 (billed by PT 50) $59.12 Per Week Provider may bill once per seven days when the patient has been seen at least once during the month; Providers may bill with Induction during the first week only. Cannot bill with E&M codes. Cannot bill with H0014 (billed by PT 50). Cannot bill with H0047. Cannot bill with H0014 (billed by PT 50). N/A Cannot bill with H0020. Cannot bill with H0014 (billed by PT 50) W9521 Buprenorphine guest dosing $8.45 Per day receiving medication at guest program Guest dosing may be billed once per day that the patient is receiving their medication at the guest dosing program. One patient is eligible for up to 30 days of guest dosing per year. Additional days may be used with clinical reasoning. N/A whichever is lower. 1 Revised 1/31/19

Medication management provided by Physicians, Nurse Practitioners, and Physician Assistants may be reimbursed using E&M codes. 99211: 99212: 99213: Management, including Rx -Minimal) Management, including Rx -Straight forward) Management, including Rx -Low complexity) $21.99 Per visit $44.57 Per visit $73.65 Per visit For most providers and most participants, twelve times a year will be sufficient. Cannot bill with H0016. Cannot bill with H0014 (billed by PT 50). 99214: 99215: Management, including Rx -Moderately $108.50 Per visit complex) Management, including Rx -Highly complex) $146.22 Per visit All lab tests are included in the bundled rate for OTPs. OTPs negotiate their rates with labs directly. Provider Type 50: OHCQ Certified of Licensed Substance Use Disorder Treatment Program H0001 Alcohol and/or Drug Assessment $152.91 Per assessment Can only be billed once per 12-months per participant per provider unless there is more than a 30 day break in treatment. N/A H0004 Individual Outpatient Therapy $21.54 Per 15 minute increment Providers may not bill for more than six units per day per participant. Cannot bill with H0015 or H2036. Cannot be billed by a PT 50 concurrent with any PT 32 claims. H0005 Group Outpatient Therapy $42.00 H0015 Intensive Outpatient (IOP) $134.60 Per 60-90 minute session Per diem with a minimum of 2 hours of service per day H2036 Partial Hospitalization $139.98 Per diem H2036: Modifier 22 H0014 Partial hospitalization (6+ hrs/day of services) ADAA Certified Ambulatory Detox Program $226.13 Per diem Provider may not bill for more than one Level I Group counseling session per day per participant. Providers may bill for maximum of 4 days per week. Services for participants who require a minimum of 9 hrs of service per week for an adult and 6 hrs per week for adolescents. Providers may bill once per day and sessions shall be a minimum of 2 hours per day. Services for participants who require 20 weekly hours of structured outpatient treatment. Providers may bill one per day and sessions shall be a minimum of 6 hours per day. Services for participants who require 20 weekly hours of structured outpatient treatment. Cannot bill with H0015 or H2036. Cannot be billed by a PT 50 concurrent with any PT 32 claims. Cannot bill with H0004, H0005, or H2036 Cannot bill this with H0004, H0005, or H0015 Cannot bill this with H0004, H0005, or H0015 $75.38 Per diem Max of 5 days. Cannot be billed concurrent with any PT 32 claims. whichever is lower. 2 Revised 1/31/19

Provider Type 50s that employ DATA 2000 WAIVED PRACITIONERS may be reimbursed for Medication Assisted Treatment for SUD using E&M codes. 99201: 99202: 99203: Management, Including Rx-Minimal, new patient) Management, Including Rx-Straight forward, new patient) Management, Including Rx-Low complexity, new patient) $45.37 Per visit $76.01 Per visit $109.40 Per visit 99204: Management, Including Rx Moderately complex, new patient) $166.09 Per visit 99205: Management, Including Rx-Highly complex, new patient) $208.77 Per visit For most providers and most participants, twelve times a year will be sufficient. Cannot bill with H0014. Cannot be billed by a PT 50 concurrent with any PT 32 claims. 99211: Management, including Rx -Minimal) $21.99 Per visit 99212: Management, including Rx -Straight forward) $44.57 Per visit 99213: Management, including Rx -Low complexity) $73.65 Per visit 99214: Management, including Rx -Moderately $108.50 Per visit complex) 99215: Management, including Rx -Highly complex) $146.22 Per visit whichever is lower. 3 Revised 1/31/19

Medication Assisted Treatment Effective 1-1-19 BUPRENORPHINE The codes below apply to PT 32, or PT 50 that is administering buprenorphine directly to patients. When the provider has ordered and paid for the drug directly through the manufacturer, the provider will reimburse based on the dosage of the administered medication to the patient. The J codes may NOT be used when prescribing the medication, or when the medication is obtained from the pharmacy where the point of sale occurred. ZUBSOLV J0572: Modifier 51 Rate Unit Service Limits ZUBSOLV must include NDC: 54123-0914-30 $4.16 1.4-0.36 mg tablet J0572 (No modifier) ZUBSOLV must include NDC: 54123-0929-30 $8.26 2.9-0.71 mg tablet May be reimbursed in combinations that reach the correct clinical dose. J0573 (No modifier) SUBOXONE J0572: Modifier SC J0574 (No modifier) BUNAVAIL J0572: J0572: Modifier HF ZUBSOLV must include NDC: 54123-0957-30 Suboxone Film Must include NDC: 12496-1202-03 Suboxone Film Must include NDC: 12496-1208-03 must include NDC: 59385-0012-01 : must include NDC 59385-0012-30 $8.31 5.7-1.4 mg tablet $4.59 2 mg $8.21 8 mg $7.65 2.1-0.3 mg film $7.43 2.1-0.3 mg film J0573: Modifier 51 must include NDC: 59385-0014-01 $8.03 4.2-0.7 mg film J0573: Modifier SC must include NDC: 59385-0014-30 $7.51 4.2-0.7 mg film J0574: Modifier 51 must include NDC: 59385-0016-01 $16.06 6.3-1 mg film J0574: Modifier SC SUBUTEX J0571: Modifier 51 J0571 (no modifier) must include NDC: 59385-0016-30 $14.90 6.3-1 mg film Rate Unit Service Limits Subutex 2 mg: NDCs below $1.25 2 mg Subutex 8 mg: NDCs below $1.83 8 mg whichever is lower. 4 Revised 1/31/19

Subutex NDC codes NDC Drug Name Price 00054-0176- 13 00054-0177- 13 00093-5378- 56 00093-5379- 56 00228-3153- 03 00228-3156- 03 00378-0923- 93 00378-0924- 93 50383-0924- 93 50383-0930- 93 whichever is lower. 5 Revised 1/31/19

VIVITROL Effective 1-1-19 The codes below apply to community based providers that are administering vivitrol directly to patients. When the provider has ordered and paid for the drug in advance, directly through the manufacturer, Medicaid will reimburse based on the dosage of the administered drug to the Medicaid patient. The J codes may NOT be used when prescribing the medication, or when the medication is obtained from the pharmacy where the point of sale occurred. Rate Unit J2315 Vivitrol: Must include NDC 65757-- 0300-01 $3.32 Per unit 96372-HG Therapeutic Injection $16.08 Per injection Service Limits Maximum of 380 units per dose. Minimum age of use is 18. Limit one injection per month. Any DATA 2000 Waived Practitioner (MD, NP, PA) and Local Health Department with DATA 2000 Waived Practitioners Rate Unit 99201 Management, Including Rx- Minimal, new patient) $45.37 Per visit 99202 Management, Including Rx- Straight forward, new patient) $76.01 Per visit 99203 Management, Including Rx- Low complexity, new patient) $109.40 Per visit 99204 Management, Including Rx- Moderately complex, new patient) $166.09 Per visit 99205 Management, Including Rx- Highly complex, new patient) $208.77 Per visit 99211 Management, including Rx - Minimal) $21.99 Per visit 99212 Management, including Rx - Straight forward) $44.57 Per visit Rate Unit 99213 Management, including Rx - Low complexity) $73.65 Per visit 99214 Management, including Rx - Moderately complex) $108.50 Per visit 99215 Management, including Rx - Highly complex) $146.22 Per visit whichever is lower. 6 Revised 1/31/19

Provider Type 54: IMD Residential SUD for Adults Effective 1-1-19 H0001 Alcohol and/or Drug Assessment $ 152.91 Per assessment W7310 ASAM Level 3.1 $ 85.00 Per diem Can only be billed if the patient is NOT assessed to meet ASAM Residential Cannot be billed within 7 days of W7330, W7350, W7370, or W7375 Levels of Care 3.3, 3.5, 3.7, or 3.7WM. Cannot be billed with any inpatient hospital based codes. Cannot be billed with any drug screen/test codes. Cannot be billed with H0015 and H2036. W7330 ASAM Level 3.3 $ 189.44 Per diem W7350 ASAM Level 3.5 $ 189.44 Per diem W7370 ASAM Level 3.7 $ 291.65 Per diem W7375 ASAM Level 3.7WM $ 354.67 Per diem RESRB Room and Board $ 45.84 Per diem Cannot be billed with any community based SUD codes on this fee schedule with the exception of H0020 and H0047. Cannot be billed with any mental health community based services except for date of admission or for services rendered by a community based psychiatrist. Cannot be billed with any drug screen/ test codes. Administrative Days for Residential SUD for Adults Effective 1-1-19 Rate Unit Service Limits W7310-HG ASAM Level 3.1 Admin Day for Consumer Awaiting Community Services $ 85.00 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting community services. W7330-HG ASAM Level 3.3 Admin Day for Consumer Awaiting Community Services $ 189.44 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting community services. W7350-HG ASAM Level 3.5 Admin Day for Consumer Awaiting Community Services $ 189.44 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting community services W7370-HG ASAM Level 3.7 Admin Day for Hospitalized Consumer $291.65 Per diem combination to hold the bed if the consumer has been hospitalized for a shortterm stay. Short term stay decided by clinical services. W7370-SC Rate Unit Service Limits ASAM Level 3.7 Admin Day for Consumer Awaiting 3.5, 3.3, or 3.1 Bed $ 189.44 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting a 3.5/3.3/3.1 bed. W7375-HG ASAM Level 3.7WM Admin Day for Hospitalized Consumer $354.67 Per diem combination to hold the bed if the consumer has been hospitalized for a shortterm stay. Short term stay decided by clinical services. W7375-SC ASAM Level 3.7WM Admin Day for Consumer Awaiting 3.7 Bed $291.65 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting a 3.7 bed. W7375-51 ASAM Level 3.7WM Admin Day for Consumer Awaiting 3.1, 3.3, or 3.5 Bed $ 189.44 Per diem combination for a short-term, clinically indicated bed hold if the consumer is awaiting a 3.5/3.3/3.1 bed. whichever is lower. 7 Revised 1/31/19

Provider Type 55: ICF-A (Under 21) 0100 (rev Residential Services (child and cost settled Per diem code) adolescent) Drug Testing s Updated 2/1/19 Labs may not bill Medicaid for tests that are sent by OTPs (Provider Type 32) or Adult Residential Service providers (Provider Type 54) as those lab drug tests are included in the providers' bundled/ inclusive rates. All tests are limited to one test per patient per day. All tests also must be medically necessary and documented in the patient's chart. Rate Unit Service Limits Presumptive Drug Testing. Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) capable of 80305 being read by direct optical observation only (eg, dipsticks, cups, $10.02 Per test cards, cartridges), includes sample validation when performed, per date of service 80305 may be billed by CLIA waived providers. All tests must be medically necessary. Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) read by 80306 instrument-assisted direct optical observation (eg, dipsticks, $13.63 Per test cups, cards, cartridges), includes sample validation when performed, per date of service Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry 80307 analyzers (eg, immunoassay, enzyme assay, TOF, MALDI, $51.40 Per test LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service 80306 and 80307 may be billed by providers with appropriate CLIA and adequate equipment and laboratory classifications. See CMS guidance for additional information: https://www.cms.gov/regulations-and- Guidance/Legislation/CLIA/index.html?redirect=/CLIA. All tests must be medically necessary. Definitive Drug Testing. Must be performed by Labs Only: Selection must reflect Medical necessity Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (eg, IA, ELISA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase)); qualitative and quantitative, all sources, includes specimen validity testing, per day, per # of drug classes as listed below. Rate Unit Service Limits G0480 Per day, 1-7 drug class(es), including matabolite(s) if performed. $90.97 Per test Rate Unit G0481 Per day, 8-14 drug class(es), including metabolite(s) if performed. $124.49 Per test These drug tests may only be billed by Provider Type 10, Laboratories. All tests must be medically necessary. whichever is lower. 8 Revised 1/31/19